1. Overall Business Performance in 2025
In 2025, Shantou Ultrasonic Instrument Research Institute Co., Ltd. (hereinafter referred to as "the Company") achieved its initial public offering and listing on the Shenzhen Stock Exchange's Growth Enterprise Market. Throughout the year, the Company adhered to a steady progress approach, focusing on independent technological innovation, enhancing quality and efficiency, and improving core competitiveness. The Company actively responded to global market fluctuations and the complexities of international trade, continuously promoting stable development of its main business. During the reporting period, the Company achieved a cumulative operating revenue of CNY 405.51 million, a year-on-year increase of 7.90%; the net profit attributable to shareholders was CNY 148.92 million, a year-on-year increase of 2.30%. By the end of 2025, the total assets of the Company amounted to CNY 1,487.68 million, a year-on-year increase of 47.87%; the asset-liability ratio was 8.53%, a decrease of 4.93% compared to the previous year.
2. Review of Major Work in 2025
(1) Adhering to Independent Technological Innovation and Continuous Product Upgrades
The Company leveraged its advantages in independent technological innovation in ultrasound and X-ray technologies to integrate and expand common technologies such as AI and automation. The product focus included portable, miniaturized, intelligent, specialized, and multimodal developments. In medical ultrasound products, the focus was on intelligent automated scanning, specialized ultrasound applications, and the development of high-end color ultrasound imaging platforms. In industrial non-destructive testing products, the focus was on automation products, industrial multimodal products, and general product development. In portable DR products, the focus was on portable camera-style, AI, dynamic imaging, and high-pressure technology development, driving product upgrades and expanding application fields. The Company also collaborated with several medical institutions on AI-based specialized ultrasound research, such as the project initiated with the National Cancer Center and the Chinese Academy of Medical Sciences Cancer Hospital, titled "Effect Evaluation of AI-assisted Automatic Volume Breast Ultrasound Technology for Breast Cancer Screening: A Multicenter Randomized Controlled Study." During the reporting period, the Company added 22 authorized patents, including 10 Chinese invention patents and 3 U.S. invention patents; 6 new software copyrights; and participated in the formulation of 4 group standards.
(2) Technological Transformation of Production and Manufacturing Base
The Company promoted upgrades to the production environment by implementing automation, information technology, and intelligent construction. This included secondary development integration and automation transformation using standardized equipment, while also connecting and promoting information technology construction. Eight special projects were established, completing the debugging of automated circuit boards and launching the factory energy monitoring system and MES information system during the reporting period.